{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:50:12Z","timestamp":1790013012452,"version":"4.0.1"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Abiraterone acetate (AA) is approved for prostate cancer at a standard dose of 1,000 mg fasting. Because of a significant food effect, a lower dose (250 mg with food\u2014AA low dose [AALD]) shows similar efficacy at 75% lower cost. In Brazil, 80% of patients rely on the public health care system, which does not cover the standard dose. Hospital de Base has been using AALD since March 2021.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>We retrospectively reviewed patients with metastatic castration-resistant prostate cancer (mCRPC) who received AALD at any treatment line, regardless of previous chemotherapy, between March 2021 and May 2023. The primary end point was prostate-specific antigen (PSA) response rate (RR; defined as a decrease of \u226550% in PSA level after 12 weeks of treatment). Secondary end points included time to treatment failure (TTF), overall survival (OS), and PSA RR \u226550% at nadir.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              Ninety-six patients were included. Sixty-three patients (65.6%) received AALD in mCRPC first-line. After a median follow-up of 24.4 months, 53 patients (60.2%) achieved the primary end point, and 65 (69.9%) achieved a PSA reduction of \u226550% at nadir. Patients treated with AALD pre-docetaxel in the mCRPC had a higher PSA response at 12 weeks (68.3%\n              <jats:italic toggle=\"yes\">v<\/jats:italic>\n              40%,\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = .015) and at nadir (76.1%\n              <jats:italic toggle=\"yes\">v<\/jats:italic>\n              53.8%,\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = .036). First-line AALD was associated with better PSA responses. The median TTF was 7.9 months and the median OS was 20.6 months. Achieving a \u226550% PSA response at 12 weeks was associated with improved TTF (13.6\n              <jats:italic toggle=\"yes\">v<\/jats:italic>\n              4.6 months, hazard ratio [HR] = 0.37,\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              &lt; .001) and OS (28.9\n              <jats:italic toggle=\"yes\">v<\/jats:italic>\n              12.2 months, HR = 0.44,\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = .004).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>AALD showed meaningful efficacy and survival outcomes. We support AALD use, especially where standard dosing is unaffordable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/go-25-00132","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:59:09Z","timestamp":1756929549000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3209-5733","authenticated-orcid":true,"given":"Julia Belone","family":"Lopes","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital de Base de S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Jos\u00e9 do Rio Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5088-4104","authenticated-orcid":true,"given":"Ana Elisa","family":"Sanches","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de Base de S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Jos\u00e9 do Rio Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8111-3311","authenticated-orcid":true,"given":"Beatriz de Menezes","family":"Dobbert","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de Base de S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Jos\u00e9 do Rio Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Forner","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de Base de S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Jos\u00e9 do Rio Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8556-7131","authenticated-orcid":true,"given":"Jo\u00e3o Pedro","family":"Homse Netto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de Base de S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Jos\u00e9 do Rio Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7840-4790","authenticated-orcid":true,"given":"Luiza","family":"Fadul","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de Base de S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Jos\u00e9 do Rio Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Daniel","family":"Guedes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de Base de S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Jos\u00e9 do Rio Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de Base de S\u00e3o Jos\u00e9 do Rio Preto, S\u00e3o Jos\u00e9 do Rio Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7013-5408","authenticated-orcid":true,"given":"Daniel Vilarim","family":"Araujo","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Medicine, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","volume-title":"International Agency for Research on Cancer","author":"GLOBOCAN (Global Cancer Observatory)","unstructured":"GLOBOCAN (Global Cancer Observatory): International Agency for Research on Cancer. World Health Organization (WHO) Iniciative. https:\/\/gco.iarc.fr\/today\/home"},{"key":"e_1_3_6_3_2","article-title":"Low-dose abiraterone in metastatic prostate cancer: Is it practice changing? Facts and facets","author":"Patel A","unstructured":"Patel A, Tannock IF Srivastava P, et al: Low-dose abiraterone in metastatic prostate cancer: Is it practice changing? Facts and facets. JCO Glob Oncol 10.1200\/JGO.19.00341","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_6_4_2","volume-title":"SEER*Explorer: An Interactive Website for SEER Cancer Statistics. Surveillance Research Program","author":"National Cancer Institute","year":"2025","unstructured":"National Cancer Institute: SEER*Explorer: An Interactive Website for SEER Cancer Statistics. Surveillance Research Program. National Cancer Institute, 2025. SEER 21 registries https:\/\/seer.cancer.gov\/statistics-network\/explorer\/.Datasource(s):SEERIncidenceData,November2024Submission(1975-2022"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10365.x"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198801102-00037"},{"issue":"3","key":"e_1_3_6_7_2","first-page":"154","article-title":"The current state of hormonal therapy for prostate cancer","volume":"52","author":"Hellerstedt BA","year":"2002","unstructured":"Hellerstedt BA, Pienta KJ: The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52(3):154-179, 2002","journal-title":"CA Cancer J Clin"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70379-0"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02437-5"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.564"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.4381"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.06.004"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.31557\/apjcb.2024.9.4.447-454"},{"key":"e_1_3_6_21_2","unstructured":"NCCN: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)\u2014Version 2.2023\u2014July 17 2023\u2014Acetato de abiraterona is recommended by the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) as a treatment option for castration resistant prostate cancer. https:\/\/www.nccn.org"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1105-8"},{"key":"e_1_3_6_23_2","article-title":"Consensus on the treatment and Follow-Up for metastatic castration-resistant prostate cancer: A report from the first global prostate cancer consensus conference for developing countries (PCCCDC)","author":"Maluf FC","unstructured":"Maluf FC, Pereira FMT, Silva AG, et al: Consensus on the treatment and Follow-Up for metastatic castration-resistant prostate cancer: A report from the first global prostate cancer consensus conference for developing countries (PCCCDC). JCO Glob Oncol 10.1200\/GO.20.00511","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_3_6_25_2","volume-title":"Jamovi (Version 2.5) [Computer Software]","author":"The Jamovi Project","year":"2024","unstructured":"The Jamovi Project: Jamovi (Version 2.5) [Computer Software]. 2024. https:\/\/www.jamovi.org"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.09.016"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1853"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.07.004"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1173042"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.196"},{"key":"e_1_3_6_31_2","first-page":"e-20230413","article-title":"Prescription pattern of abiraterone in Brazil\u2014A survey of medical oncologists","volume":"19","author":"Homse-Netto JP","year":"2023","unstructured":"Homse-Netto JP, Aleixo-Fadul L, Soler JA., et al: Prescription pattern of abiraterone in Brazil\u2014A survey of medical oncologists. Braz J Oncol 19:e-20230413, 2023","journal-title":"Braz J Oncol"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-25-00132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:59:15Z","timestamp":1756929555000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-25-00132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1200\/GO-25-00132"],"URL":"https:\/\/doi.org\/10.1200\/go-25-00132","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2025-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500132"}}